ATE359300T1 - Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlung - Google Patents
Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlungInfo
- Publication number
- ATE359300T1 ATE359300T1 AT02717361T AT02717361T ATE359300T1 AT E359300 T1 ATE359300 T1 AT E359300T1 AT 02717361 T AT02717361 T AT 02717361T AT 02717361 T AT02717361 T AT 02717361T AT E359300 T1 ATE359300 T1 AT E359300T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer
- flt4
- vegfr
- target
- polypeptides
- Prior art date
Links
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 title abstract 3
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 238000011394 anticancer treatment Methods 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000001514 detection method Methods 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/765,534 US7034105B2 (en) | 1992-10-09 | 2001-01-19 | FLT4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE359300T1 true ATE359300T1 (de) | 2007-05-15 |
Family
ID=27805582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02717361T ATE359300T1 (de) | 2001-01-19 | 2002-01-22 | Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlung |
Country Status (10)
Country | Link |
---|---|
US (3) | US8940695B2 (de) |
EP (1) | EP1353952B1 (de) |
JP (2) | JP4669984B2 (de) |
CN (1) | CN1494552A (de) |
AT (1) | ATE359300T1 (de) |
AU (1) | AU2002248372B8 (de) |
CA (1) | CA2435503C (de) |
DE (1) | DE60219419T2 (de) |
NO (1) | NO20033285L (de) |
WO (1) | WO2002060950A2 (de) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1382679A3 (de) | 1995-09-08 | 2004-11-10 | Genentech, Inc. | Antagonisten gegen Vaskuläres Endothelzellen Wachstumsfaktor-verwandtes Protein (VRP) |
WO2000058511A1 (en) | 1999-03-26 | 2000-10-05 | Ludwig Institute For Cancer Research | Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3) |
JP4669984B2 (ja) | 2001-01-19 | 2011-04-13 | ベジェニクス リミテッド | 腫瘍画像化のターゲットとしてのF1t4(VEGFR−3)および抗腫瘍療法 |
US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
WO2004065621A1 (en) | 2002-03-01 | 2004-08-05 | Dyax Corp. | Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
DE10242663A1 (de) * | 2002-09-13 | 2004-03-25 | Forschungszentrum Karlsruhe Gmbh | Verfahren zur Identifizierung von Inhibitoren in vivo |
ES2692166T3 (es) | 2003-03-03 | 2018-11-30 | Dyax Corp. | Péptidos que se unen específicamente al receptor de HGF (cMet) y usos de los mismos |
WO2005087808A2 (en) * | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Growth factor binding constructs materials and methods |
US20060024302A1 (en) | 2004-03-05 | 2006-02-02 | Ludwig Institute For Cancer Research | Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same |
DE602006020881D1 (de) | 2005-08-15 | 2011-05-05 | Vegenics Pty Ltd | Enen eigenschaften |
US9127302B2 (en) | 2005-09-20 | 2015-09-08 | Janssen Diagnostics, Llc | System for the detection and enumeration of suspect target cells in a mixed cell population |
US9134237B2 (en) * | 2005-09-20 | 2015-09-15 | Janssen Diagnotics, LLC | High sensitivity multiparameter method for rare event analysis in a biological sample |
IL172297A (en) * | 2005-10-03 | 2016-03-31 | Compugen Ltd | Soluble vegfr-1 variants for the diagnosis of preeclampsia |
PT2043662E (pt) * | 2006-07-26 | 2015-11-25 | Intrexon Corp | Métodos e composições para tratamento de doença |
WO2008093246A2 (en) * | 2007-02-02 | 2008-08-07 | Vegenics Limited | Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis |
CN101564540B (zh) * | 2008-04-22 | 2011-05-11 | 上海交通大学医学院附属瑞金医院 | 一种Gd-DTPA-Polylysine-McAb联结体的制备方法 |
WO2010021993A1 (en) * | 2008-08-19 | 2010-02-25 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease |
DE102009030321A1 (de) * | 2009-06-24 | 2011-01-05 | Siemens Aktiengesellschaft | Verfahren zur Abbildung von Tumorgewebe |
WO2011056494A1 (en) * | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
WO2011071577A1 (en) * | 2009-12-11 | 2011-06-16 | Genentech, Inc. | Anti-vegf-c antibodies and methods using same |
EP2538965B1 (de) | 2010-02-25 | 2017-04-12 | Schepens Eye Research Institute | Therapeutische zusammensetzungen zur behandlung des syndroms des trockenen auges |
ES2575160T3 (es) | 2010-03-15 | 2016-06-24 | The Board Of Trustees Of The University Of Illinois | Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G |
AR082641A1 (es) * | 2010-09-07 | 2012-12-19 | Imclone Llc | Composiciones de anticuerpo anti-vegfr-3 |
US9029502B2 (en) | 2010-12-20 | 2015-05-12 | The Regents Of The University Of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
WO2013184209A1 (en) | 2012-06-04 | 2013-12-12 | Ludwig Institute For Cancer Research Ltd. | Mif for use in methods of treating subjects with a neurodegenerative disorder |
WO2014064203A1 (en) | 2012-10-26 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis |
CA2901226C (en) | 2013-02-18 | 2020-11-17 | Vegenics Pty Limited | Vascular endothelial growth factor binding proteins |
US10274503B2 (en) | 2013-05-08 | 2019-04-30 | Vegenics Pty Limited | Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis |
KR102060187B1 (ko) * | 2013-07-19 | 2019-12-27 | 삼성전자주식회사 | Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도 |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
EP3250609A4 (de) | 2015-01-26 | 2018-07-11 | The University of Chicago | Il13ra-alpha-2-bindende wirkstoffe und verwendung davon bei der krebsbehandlung |
US20180170992A1 (en) | 2015-01-26 | 2018-06-21 | The University Of Chicago | CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2 |
JP7084878B2 (ja) | 2016-05-16 | 2022-06-15 | 武田薬品工業株式会社 | 抗第IX因子Padua抗体 |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
CA3160316A1 (en) | 2019-11-07 | 2021-05-14 | The Board Of Trustees Of The University Of Illinois | Peptides and methods of treating sepsis, atherosclerosis, thrombosis, stroke, heart attack and inflammation |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4652639A (en) * | 1982-05-06 | 1987-03-24 | Amgen | Manufacture and expression of structural genes |
US4543439A (en) * | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
US4933294A (en) * | 1984-01-30 | 1990-06-12 | Icrf Patents Limited | Method of detecting truncated epidermal growth factor receptors |
ES2006109A6 (es) * | 1987-03-11 | 1989-04-01 | Erba Carlo Spa | Un procedimiento para preparar un conjugado de inmunoglobulina. |
DE721983T1 (de) | 1988-01-22 | 2002-07-04 | Zymogenetics Inc | Verfahren zur herstellung von biologisch-aktive Dimerpeptiden |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
CA2011450C (en) * | 1989-03-07 | 2002-06-04 | Tadatsugu Taniguchi | Recombinant b-chain of the il-2 receptor |
DK0474744T3 (da) | 1989-05-22 | 1994-11-21 | Zymogenetics Inc | PDGF-alfa-receptor |
US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
CA2100559C (en) | 1991-01-31 | 2007-05-22 | David Wolf | Domains of extracellular region of human platelet derived growth factor receptor polypeptides |
US5256766A (en) * | 1991-02-19 | 1993-10-26 | The Regents Of The University Of California | Recombinant thrombin receptor and related pharmaceuticals |
CA2083401C (en) | 1991-02-22 | 2003-03-25 | Bruce I. Terman | Identification of a novel human receptor tyrosine kinase gene |
US5231001A (en) * | 1991-03-14 | 1993-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor |
US5270458A (en) * | 1991-04-02 | 1993-12-14 | The Trustees Of Princeton University | Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2 |
US5185438A (en) * | 1991-04-02 | 1993-02-09 | The Trustees Of Princeton University | Nucleic acids encoding hencatoporetic stem cell receptor flk-2 |
US5367057A (en) * | 1991-04-02 | 1994-11-22 | The Trustees Of Princeton University | Tyrosine kinase receptor flk-2 and fragments thereof |
CA2078539C (en) * | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
HUT69792A (en) | 1992-01-09 | 1995-09-28 | Helsinki University Holding Lt | Tie, a nocel endothelial cell receptor tyrosine kinase |
CA2128722A1 (en) | 1992-01-22 | 1993-08-05 | William I. Wood | Novel protein tyrosine kinases |
US5635177A (en) * | 1992-01-22 | 1997-06-03 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
US6331302B1 (en) * | 1992-01-22 | 2001-12-18 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
US5776427A (en) * | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
US6107046A (en) * | 1992-10-09 | 2000-08-22 | Orion Corporation | Antibodies to Flt4, a receptor tyrosine kinase and uses thereof |
US6824777B1 (en) * | 1992-10-09 | 2004-11-30 | Licentia Ltd. | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
US5776755A (en) * | 1992-10-09 | 1998-07-07 | Helsinki University Licensing, Ltd. | FLT4, a receptor tyrosine kinase |
RO119721B1 (ro) | 1992-10-28 | 2005-02-28 | Genentech Inc. | Antagonişti ai factorului de creştere al celulelor vasculare endoteliale |
US5763441A (en) * | 1992-11-13 | 1998-06-09 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
US5712395A (en) * | 1992-11-13 | 1998-01-27 | Yissum Research Development Corp. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
DE4337197C1 (de) * | 1993-10-30 | 1994-08-25 | Biotest Pharma Gmbh | Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore |
US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
US6040157A (en) * | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US6734285B2 (en) * | 1994-03-08 | 2004-05-11 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 proteins and compositions |
US6608182B1 (en) * | 1994-03-08 | 2003-08-19 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 2 |
US5932540A (en) * | 1994-03-08 | 1999-08-03 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
DK0751992T3 (da) * | 1994-03-08 | 2006-03-06 | Human Genome Sciences Inc | Karendotelvækstfaktor 2 |
GB9410534D0 (en) * | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | Improvements in or relating to growth factor inhibitors |
CA2192235C (en) * | 1994-06-09 | 2011-02-15 | Kari Alitalo | Flt4 receptor tyrosine kinase and its use in diagnosis and therapy |
US5763733A (en) * | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
US6403088B1 (en) * | 1995-08-01 | 2002-06-11 | Helsinki University Licensing, Ltd. | Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3) |
US6245530B1 (en) * | 1995-08-01 | 2001-06-12 | Ludwig Institute For Cancer Research | Receptor ligand |
WO1998033917A1 (en) | 1994-11-14 | 1998-08-06 | The Ludwig Institute For Cancer Research | Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof |
US6645933B1 (en) * | 1995-08-01 | 2003-11-11 | Helsinki University Licensing Ltd. Oy | Receptor ligand VEGF-C |
US6221839B1 (en) * | 1994-11-14 | 2001-04-24 | Helsinki University Licensing Ltd. Oy | FIt4 ligand and methods of use |
US6130071A (en) * | 1997-02-05 | 2000-10-10 | Helsinki University Licensing, Ltd. | Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof |
US6361946B1 (en) * | 1997-02-05 | 2002-03-26 | Licentia Ltd | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
EP1382679A3 (de) | 1995-09-08 | 2004-11-10 | Genentech, Inc. | Antagonisten gegen Vaskuläres Endothelzellen Wachstumsfaktor-verwandtes Protein (VRP) |
DE69638142D1 (de) | 1995-09-29 | 2010-04-15 | Univ Siena | Regulierte Gene und ihre Verwendungen |
US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
ES2242227T5 (es) | 1996-07-15 | 2011-12-09 | Chugai Seiyaku Kabushiki Kaisha | Nuevo factor de tipo vegf. |
DE69739469D1 (de) * | 1996-08-23 | 2009-07-30 | Vegenics Ltd | Rekombinanter vasculärer Endothelzellen Wachstumsfaktor D (VEGF-D) |
US7125714B2 (en) * | 1997-02-05 | 2006-10-24 | Licentia Ltd. | Progenitor cell materials and methods |
JP2003517265A (ja) | 1997-12-24 | 2003-05-27 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | 血管内皮増殖因子dを発現する発現ベクターおよび細胞系、およびメラノーマを治療する方法 |
NZ529063A (en) * | 1998-10-09 | 2005-07-29 | Ludwig Inst Cancer Res | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
JP2003517275A (ja) * | 1998-11-02 | 2003-05-27 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | 哺乳動物vegfレセプター−2に結合し、これを活性化するオルフウイルスnz2由来の血管内皮細胞増殖因子様タンパク質 |
US6383484B1 (en) | 1998-12-21 | 2002-05-07 | Ludwig Institute For Cancer Research | Antibodies to truncated VEGF-D and thereof |
KR20010101981A (ko) | 1999-02-08 | 2001-11-15 | 벤슨 로버트 에이치. | 혈관 내피 성장 인자-2 |
US6393484B1 (en) * | 1999-04-12 | 2002-05-21 | International Business Machines Corp. | System and method for controlled access to shared-medium public and semi-public internet protocol (IP) networks |
RS50073B (sr) | 1999-06-08 | 2009-01-22 | Regeneron Pharmaceuticals I.N.C., | Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama |
EP1206490A1 (de) | 1999-08-16 | 2002-05-22 | Universita Degli Studi Di Siena | Vegf-d und dessen verwendung in der foerderung von angiogenese |
WO2001052875A1 (en) * | 2000-01-18 | 2001-07-26 | Ludwig Institute For Cancer Research | Vegf-d/vegf-c/vegf peptidomimetic inhibitor |
EP1259626B1 (de) * | 2000-02-25 | 2007-10-31 | Ludwig Institute For Cancer Research | Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren |
AU4194601A (en) * | 2000-03-02 | 2001-09-12 | Ludwig Institute For Cancer Research | Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor |
US20020102260A1 (en) * | 2000-03-02 | 2002-08-01 | Marc Achen | Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue |
CA2407970A1 (en) * | 2000-05-03 | 2001-11-08 | Ludwig Institute For Cancer Research | A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof |
US7273751B2 (en) * | 2000-08-04 | 2007-09-25 | Human Genome Science, Inc. | Vascular endothelial growth factor-2 |
AU2001296521A1 (en) * | 2000-10-02 | 2002-04-15 | St. Elizabeth's Medical Center Of Boston, Inc. | Use of lymphangiogenic agents to treat lymphatic disorders |
US20020197691A1 (en) * | 2001-04-30 | 2002-12-26 | Myriad Genetics, Incorporated | FLT4-interacting proteins and use thereof |
US20030211988A1 (en) * | 2001-01-09 | 2003-11-13 | Epstein Stephen E | Enhancing lymph channel development and treatment of lymphatic obstructive disease |
US7611711B2 (en) * | 2001-01-17 | 2009-11-03 | Vegenics Limited | VEGFR-3 inhibitor materials and methods |
JP4669984B2 (ja) | 2001-01-19 | 2011-04-13 | ベジェニクス リミテッド | 腫瘍画像化のターゲットとしてのF1t4(VEGFR−3)および抗腫瘍療法 |
CA2444624A1 (en) * | 2001-04-13 | 2002-10-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US20030170786A1 (en) * | 2001-04-13 | 2003-09-11 | Rosen Craig A. | Vascular endothelial growth factor 2 |
ATE470676T1 (de) * | 2001-04-13 | 2010-06-15 | Human Genome Sciences Inc | Anti-vegf-2 antikörper |
US20030180294A1 (en) * | 2002-02-22 | 2003-09-25 | Devries Gerald W. | Methods of extending corneal graft survival |
US20030232437A1 (en) * | 2002-06-17 | 2003-12-18 | Isis Pharmaceuticals Inc. | Antisense modulation of VEGF-C expression |
US20030228283A1 (en) * | 2002-05-03 | 2003-12-11 | Ludwig Institute For Cancer Research | Preventing secondary lymphedema with VEGF-D DNA |
CN1684706A (zh) | 2002-07-23 | 2005-10-19 | 路德维格癌症研究所 | 活化或抑制vegf-d和vegf-c的方法和组合物 |
WO2004084353A1 (de) * | 2003-03-17 | 2004-09-30 | Lear Corporation | Elektrisches kontaktelement für einen flachleiter |
WO2005087808A2 (en) * | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Growth factor binding constructs materials and methods |
-
2002
- 2002-01-22 JP JP2002561517A patent/JP4669984B2/ja not_active Expired - Lifetime
- 2002-01-22 EP EP02717361A patent/EP1353952B1/de not_active Expired - Lifetime
- 2002-01-22 CA CA2435503A patent/CA2435503C/en not_active Expired - Lifetime
- 2002-01-22 AU AU2002248372A patent/AU2002248372B8/en not_active Expired
- 2002-01-22 DE DE60219419T patent/DE60219419T2/de not_active Expired - Lifetime
- 2002-01-22 WO PCT/US2002/001784 patent/WO2002060950A2/en active IP Right Grant
- 2002-01-22 CN CNA028060490A patent/CN1494552A/zh active Pending
- 2002-01-22 AT AT02717361T patent/ATE359300T1/de not_active IP Right Cessation
-
2003
- 2003-07-21 NO NO20033285A patent/NO20033285L/no unknown
-
2006
- 2006-01-06 US US11/327,075 patent/US8940695B2/en active Active
-
2009
- 2009-10-30 JP JP2009251019A patent/JP2010088433A/ja not_active Withdrawn
-
2014
- 2014-11-17 US US14/543,277 patent/US9260526B2/en not_active Expired - Fee Related
-
2016
- 2016-01-06 US US14/989,379 patent/US20160200793A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002060950A2 (en) | 2002-08-08 |
EP1353952B1 (de) | 2007-04-11 |
US20160200793A1 (en) | 2016-07-14 |
CN1494552A (zh) | 2004-05-05 |
AU2002248372B2 (en) | 2007-08-23 |
US9260526B2 (en) | 2016-02-16 |
EP1353952A2 (de) | 2003-10-22 |
US20150141622A1 (en) | 2015-05-21 |
DE60219419D1 (de) | 2007-05-24 |
CA2435503C (en) | 2011-02-22 |
US8940695B2 (en) | 2015-01-27 |
JP2004532004A (ja) | 2004-10-21 |
US20060177901A1 (en) | 2006-08-10 |
NO20033285D0 (no) | 2003-07-21 |
JP2010088433A (ja) | 2010-04-22 |
WO2002060950A3 (en) | 2003-02-06 |
JP4669984B2 (ja) | 2011-04-13 |
DE60219419T2 (de) | 2007-08-16 |
AU2002248372B8 (en) | 2008-03-20 |
CA2435503A1 (en) | 2002-08-08 |
WO2002060950B1 (en) | 2003-11-27 |
NO20033285L (no) | 2003-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE359300T1 (de) | Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlung | |
DE69942981D1 (de) | Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie | |
UA89017C2 (uk) | ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b | |
CY1119291T1 (el) | Πολυσθενη αντισωματα και χρησεις για αυτα | |
PL2097453T3 (pl) | Przeciwciała monoklonalne przeciw ludzkiemu receptorowi hormonu anty-Mullerowskiego typu II (AMHR-II) | |
ATE497603T1 (de) | Drei-hybrid-assaysystem | |
WO2005077981A3 (en) | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES | |
DK1951759T3 (da) | Anti-EGFR-antistoffer | |
WO2006113546A3 (en) | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers | |
TW200631594A (en) | Toll like receptor 3 antagonists, methods and uses | |
ATE462493T1 (de) | Integriertes system mit modularen mikrofluidischen komponenten | |
WO2006066024A8 (en) | Pancreatic polypeptide family motifs, polypeptides and methods comprising the same | |
EP1983002A3 (de) | Tyrosinphosphorylations-Stellen und spezifische Antikörper | |
WO2003048301A3 (en) | Anti-hla-dr antibodies and the methods of using thereof | |
WO2007051164A8 (en) | Toll like receptor 3 modulators, methods and uses | |
DE602006018424D1 (de) | Peptide zum nachweis von ehrlichia ewingii antikörper | |
DE60227974D1 (de) | Diagnostische tests auf periostinbasis | |
CY1107339T1 (el) | Mu-1, μελος της οικογενειας υποδοχεα κυτοκινης | |
WO2006063028A3 (en) | Immunostimulatory compositions and uses thereof | |
WO2004066933A3 (en) | Compositions and methods for treating cancer using igsf9 and liv-1 | |
WO2003072727A3 (en) | EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER | |
ATE270332T1 (de) | Polynucleotide and polypeptide basb033 aus neisseria meningitidis und ihre verwendungen | |
WO2005046602A3 (en) | Vegf receptor antagonists | |
WO2005094159A3 (en) | Methods of identifying neoplasm-specific antibodies and uses thereof | |
DK1303539T3 (da) | Hidtil ukendt medlem af EphA-receptorfamilien |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |